What is Jardiance (empagliflozin) used for?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What Jardiance (Empagliflozin) Is Used For

Jardiance is FDA-approved for improving blood sugar control in adults with type 2 diabetes and reducing cardiovascular death in diabetic patients with established cardiovascular disease, but its most clinically significant use based on mortality and morbidity outcomes is for treating heart failure (both reduced and preserved ejection fraction) and chronic kidney disease, regardless of diabetes status. 1

FDA-Approved Indications

Jardiance has two official FDA indications 1:

  • Type 2 diabetes management: As an adjunct to diet and exercise to improve glycemic control in adults
  • Cardiovascular death reduction: In adult patients with type 2 diabetes and established cardiovascular disease

Important limitation: Jardiance is NOT recommended for type 1 diabetes or diabetic ketoacidosis treatment 1

Evidence-Based Clinical Uses (Guideline-Supported)

Heart Failure Treatment (Primary Indication by Outcomes)

Jardiance significantly reduces cardiovascular death and heart failure hospitalization in patients with heart failure, with or without diabetes 2. This represents the strongest mortality benefit:

  • Heart failure with reduced ejection fraction (HFrEF): 35% reduction in heart failure hospitalization, with consistent mortality benefits 2
  • Heart failure with preserved ejection fraction (HFpEF): 21% reduction in composite cardiovascular death or heart failure hospitalization (HR 0.79,95% CI 0.69-0.90) 2, 3
  • Benefits occur regardless of diabetes status 2, 4

The 2025 ADA guidelines and 2022 AHA/ACC/HFSA guidelines now position SGLT2 inhibitors like empagliflozin as foundational therapy for heart failure 5, 3.

Chronic Kidney Disease Protection

Empagliflozin reduces CKD progression and cardiovascular events in patients with eGFR ≥20 mL/min/1.73 m² and albuminuria 6:

  • 50% reduction in composite renal outcomes (chronic dialysis, transplantation, or sustained eGFR reduction; HR 0.50,95% CI 0.32-0.77) 2
  • Slows eGFR decline over time 6, 7
  • Reduces macroalbuminuria and microalbuminuria progression 7
  • Benefits extend to patients with or without diabetes 6, 4

Cardiovascular Risk Reduction in Type 2 Diabetes

In the EMPA-REG OUTCOME trial, empagliflozin demonstrated 8, 2, 9:

  • 14% reduction in major adverse cardiovascular events (MACE)
  • 38% reduction in cardiovascular death
  • 32% reduction in all-cause mortality

These benefits were specifically in diabetic patients with established cardiovascular disease 8, 9.

Mechanism and Additional Effects

Empagliflozin works by blocking glucose reabsorption in the kidney (SGLT2 inhibition), producing 5, 7:

  • Glycemic control: HbA1c reduction of 0.5-0.8% 5, 7
  • Weight loss: Approximately 2 kg reduction 8, 5
  • Blood pressure reduction: Systolic ~4 mmHg, diastolic ~2 mmHg 8, 5
  • Low hypoglycemia risk when used alone 5

Dosing Considerations

Standard dose: 10 mg once daily (the dose tested in cardiovascular and renal outcomes trials) 8, 5

  • 25 mg daily may provide additional glucose lowering but no additional cardiovascular or renal benefit 8
  • Glucose-lowering effect diminishes with eGFR <45 mL/min/1.73 m², but continue for cardiovascular and kidney benefits until dialysis 5
  • Can be initiated with eGFR >30 mL/min/1.73 m² (some trial data support use down to eGFR 20) 6

Key Safety Considerations

Common adverse effects 8, 5:

  • Genital mycotic infections (10-15% in women, lower in men)
  • Urinary tract infections (monitor in elderly ≥75 years: 15-16% incidence)
  • Volume depletion (especially in elderly ≥75 years: 4.4% with 25 mg dose)

Serious but rare risks 5:

  • Diabetic ketoacidosis (including euglycemic DKA): Discontinue 3-4 days before surgery and during critical illness
  • Fournier's gangrene (necrotizing fasciitis): Rare but requires prompt treatment
  • Acute kidney injury: Monitor kidney function, especially with volume depletion

Contraindications 8, 1:

  • Severe renal impairment (eGFR <30 mL/min/1.73 m² per label, though evidence supports use to eGFR 20)
  • End-stage renal disease or dialysis
  • Type 1 diabetes (increased DKA risk)

Clinical Positioning

The 2025 ADA Standards of Care prioritize empagliflozin for patients with 5:

  1. Type 2 diabetes with heart failure (any ejection fraction)
  2. Type 2 diabetes with chronic kidney disease (eGFR ≥20, albuminuria present)
  3. Type 2 diabetes with established atherosclerotic cardiovascular disease

The 2021 CCS/CHFS guidelines recommend SGLT2 inhibitors like empagliflozin as foundational therapy for all patients with HFrEF, regardless of diabetes status 4.

The drug's value extends far beyond glucose control—its primary clinical utility is preventing cardiovascular death, heart failure hospitalization, and kidney disease progression 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.